Key Takeaways:

  • FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, potentially ending large-scale compounding of these GLP-1 drugs permanently
  • The proposal targets 503B outsourcing facilities that produce compounded drugs in bulk, but doesn't affect 503A pharmacies that fill individual prescriptions
  • Public comment period runs through June 29, 2026, before FDA makes final decision that could reshape affordable GLP-1 access

FDA Takes Aim at Large-Scale GLP-1 Compounding

The FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. This move represents the agency's most significant step yet to permanently restrict access to compounded GLP-1 medications.

The three chemicals are the active ingredients in drugs made by Novo Nordisk and Eli Lilly for weight loss and diabetes, including Wegovy, Ozempic, Zepbound and Mounjaro, but the FDA carefully reviewed the nominations it received and did not identify sufficient evidence to include these compounds on the 503B bulks list.

"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," said FDA Commissioner Marty Makary, M.D., M.P.H. "This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process."

Understanding the 503B Framework and What's at Stake

The 503B bulks list identifies bulk drug substances that outsourcing facilities may use in compounding under the conditions of section 503B of the Federal Food, Drug, and Cosmetic Act. In most cases, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance appears on the 503B bulks list, or the compounded drug is on the FDA's drug shortage list.

Under the 503B framework, outsourcing facilities may only use bulk drug substances if the substance is on the bulks list or the compounded drug is on the shortage list. With neither condition met for these 3 agents, a formal exclusion would foreclose any future pathway for bulk compounding, even in the event of a new shortage designation.

The agency's proposal specifically targets 503B outsourcing facilities, which manufacture compounded drugs in bulk with or without prescription and are largely regulated by FDA guidelines. The proposal does not impact 503A pharmacies, which make compounded drugs according to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA.

The Rise and Fall of Compounded GLP-1 Access

The announcement is the latest chapter in a regulatory saga that has unfolded since 2022, when skyrocketing demand for glucagon-like peptide-1 (GLP-1) receptor agonists outpaced brand-name manufacturing capacity and opened the door to a booming compounding market. Compounded versions of GLP-1s accounted for up to 30% of U.S. supply of the drugs in 2024, and telehealth companies have continued to sell them despite manufacturer opposition.

Demand-driven shortages beginning in 2022 enabled widespread compounding at around $150–$300 per month versus over $1,000 branded pricing, until FDA declared shortages resolved and imposed wind-down enforcement deadlines. However, most telehealth companies use 503A pharmacies to fill their personalized compounded doses, said Rosalie Hoyle, a research scientist at health consultancy Avalere, adding the exclusion from the 503B bulks list may not operationally impact current compounding of GLP-1 drugs.

The compounding market emerged as a lifeline for many people who couldn't afford brand-name medications or access them through insurance. This created a parallel healthcare ecosystem where people could access these medications at a fraction of the cost, often through online platforms and telehealth providers who connected them with compounding pharmacies.

Safety Concerns Drive Regulatory Pressure

As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials—some of which required hospitalization.

Compounded drugs generally are less expensive than the FDA-approved drugs they mimic, and the availability of cheaper alternatives to the expensive name-brand weight loss drugs has driven many people to them. But concerns about counterfeit products entering the market through online channels have further reinforced the FDA's enforcement focus.

The safety issues aren't theoretical. Reports have included hospitalizations from dosing mistakes, contaminated products, and medications that didn't contain the active ingredients promised. The FDA has been particularly concerned about people purchasing what they believed were legitimate compounded medications from unregulated online sources.

Industry Response and Market Impact

Lilly and Novo commended the FDA's confirmation that there is no clinical need to compound these drugs. "That means there is no basis for compounders to make tirzepatide knockoffs," a spokesperson for Lilly told Reuters. "The agency's notice today reaffirms that compounding is meant to be a rare and limited exception to FDA's gold-standard drug approval framework," a Novo spokesperson said.

The Alliance for Pharmacy Compounding is reviewing the FDA's proposed rule addressing the 503B Bulks List, including the agency's proposal not to include liraglutide, semaglutide, and tirzepatide. APC believes it is important that any final policy fully reflect both the statutory framework established by Congress and the practical realities of patient care. Compounding has long served as a critical, complementary component of the healthcare system, particularly in times of supply disruption.

The FDA is now inviting interested parties to submit comments electronically through the docket by June 29, 2026. The agency will consider submitted comments before making a final determination.

What This Means for You

This proposal could significantly impact your access to affordable GLP-1 medications. While 503A compounding (individual prescriptions through state-licensed pharmacies) remains available for now, the exclusion from the 503B bulks list would eliminate the large-scale compounding operations that have helped keep costs lower for many people.

If you're currently using a compounded GLP-1 medication, don't panic — but do start planning. Many telehealth providers have already adapted their networks to work primarily with 503A pharmacies. However, you may see price increases or supply changes as the industry adjusts to these new restrictions.

Consider exploring manufacturer savings programs for brand-name medications, or compare costs across different options to find the most affordable path forward. You might also want to discuss alternative treatment approaches with your healthcare provider or explore GLP-1 clinics in your area that can help you navigate both branded and compounded options while they remain available.

The key is staying informed and proactive about your treatment options. This regulatory change doesn't happen overnight, and you have time to explore alternatives that work for your budget and healthcare needs.

Sources: